# Boosting Osimertinib Blood Brain Barrier Penetration

Source: https://onco.cc/trials/nct07485452/  
OnCo record `nct07485452` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by Maastricht University Medical Center, now recruiting.

## Summary

Boosting Osimertinib Blood Brain Barrier Penetration is a phase 2, interventional study registered as NCT07485452 by Maastricht University Medical Center, with a registry enrolment figure of 7 participants, started 2026-06 and due to reach its primary completion in 2027-06. Interventions recorded: Osimertinib & febuxostat. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Effect of combining osimertinib with febuxostat on osimertinib CSF:plasma ratio in patients with EGFR NSCLC without CNS metastases. Lung eligibility wording from the registry: "The patient has metastatic EGFR-mutated NSCLC and is treated with osimertinib as part of regular care with CT-confirmed stable disease or better". Sites: Netherlands. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: OSIBBBOOST
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07485452
- Phase: 2
- Setting: Boosting Osimertinib Blood Brain Barrier Penetration in Patients With Epidermal Growth Factor Receptor Mutated Non-small Cell Lung Cancer
- Sponsor: Maastricht University Medical Center
- Enrolled: 7

## Sources

- ClinicalTrials.gov NCT07485452: https://clinicaltrials.gov/study/NCT07485452

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07485452.json